# LEAP-006 (NCT03829319)

> Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

No report yet. It can be ordered.

- Drugs tested: lenvatinib plus pembrolizumab
- Indication: first-line metastatic nonsquamous non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03829319
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Nonsquamous Non-small Cell Lung Cancer
- Interventions: Pembrolizumab; Carboplatin; Cisplatin; Pemetrexed; Lenvatinib; Placebo matching lenvatinib
- Enrollment: 761
- Primary outcome: Part 1: Number of Participants With a Dose-limiting Toxicity (DLT)
- Primary outcome: Part 1: Number of Participants Who Experienced an Adverse Event (AE)
- Primary outcome: Part 1: Number of Participants Who Discontinued Study Drug Due to an Adverse Event
- Primary outcome: Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Primary outcome: Part 2: Overall Survival (OS)

## Indexed commentary on LEAP-006 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 12 posts on X
- 2 podcast episodes

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=leap-006-nct03829319

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03829319", "email": "<work email>"}; the inbox owner confirms by the emailed link.